Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (51960)	6/16/2022 12:25:43 PM
From: Art Bechhoefer	Read Replies (1) \| Respond to of 52153

Tegsedi, the drug developed by Ionis Pharmaceuticals, is injected by the patient once a week. The patient can do the injection anywhere. No clinical supervision is needed. Onpattro, if I recall correctly, requires an injection of cortisone to avoid inflammation. Both these drugs have potential adverse side effects. Ionis is currently developing a new version of Tegsedi that will require a lower dosage and have fewer side effects. Art